ARS Pharma Q3 net loss $19.1M; neffy launch progressing; ALK deal $145M

ARS Pharmaceuticals, Inc.

2024-Q3 EPS reported -$0.43 revenue$2,568,000

Net loss of $19.1M for Q3 2024; total revenue of $2.1M including $0.6M neffy product revenue from one week of sales.
Cash, equivalents & short-term investments $204.6M at Sept 30; pro forma $349.6M after $145M upfront from ALK-Abelló deal.
FDA granted priority review for neffy 1mg sNDA; PDUFA date March 6, 2025 for children weighing 15-30 kg.
Exclusive license with ALK-Abelló for neffy in Europe, Canada, etc.; total consideration up to $465M plus double-digit royalties.
Over 5,700 HCPs reached, 1,700+ prescriptions submitted, and 1,000 allergists enrolled in neffy Experience Program since launch.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.